Carisma Therapeutics, Inc. (CARM)

The past six months have seen significant negative events impacting Carisma Therapeutics, Inc.'s stock price, with an 81.79% decrease from November 25, 2024, to October 10, 2025. Carisma Therapeutics Inc. received a delisting determination from Nasdaq due to noncompliance with listing rules, leading to a 41.6% stock plummet and suspension from trading. Carisma secured approval to transfer its listing to the OTCID market tier. Carisma stated it would attempt to sell or dispose of its remaining assets and pursue an orderly wind down of its remaining operations. Carisma Therapeutics shares were trading higher after the company announced it would receive a $5 million investment from Ocugen as part of a merger with Ocugen's subsidiary OrthoCelix. Carisma Therapeutics announced executive terminations and a wind-down in October 2025.

Carisma Therapeutics, Inc.'s products and services do not exhibit typical demand seasonality. The demand for its therapies would be driven by factors such as disease prevalence, the success of clinical trials, regulatory approvals, and market adoption, rather than seasonal consumer patterns.

Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other serious diseases, operating within the Healthcare sector and Biotechnology industry. The company utilizes a proprietary macrophage and monocyte cell engineering platform to develop therapies such as CT-0508, CT-0525, CT-1119, CT-2401, and in vivo CAR-M cell therapy. Carisma Therapeutics also has a collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies.

Carisma Therapeutics, Inc. is headquartered in Philadelphia, Pennsylvania, United States. The company focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States.

Carisma Therapeutics' brand reputation in the past year has been significantly impacted by negative events, primarily related to its financial standing and operational future. The delisting notice from Nasdaq and the subsequent suspension of trading negatively affected the company's reputation and investor confidence. The announcement of a strategic review to explore asset monetization and an "orderly wind down of its remaining operations," coupled with the unlikelihood of a meaningful cash distribution to stockholders, indicates a challenging period for the company's reputation. Several shareholder investigation firms have announced investigations into the company for potential violations of federal securities laws and/or breaches on behalf of shareholders, further highlighting reputational concerns. The announcement of executive terminations in October 2025 also contributed to a negative perception.

Carisma Therapeutics, Inc. has a mix of institutional, retail, and individual investors. Approximately 3.90% to 6.13% of the stock is held by institutional investors, while retail investors hold around 93.87%. Insiders own about 1.59% of the company's stock. Major institutional owners and shareholders include Merck & Co., Inc., Vanguard Group Inc, BlackRock, Inc., Renaissance Technologies Llc, Geode Capital Management, Llc, State Street Corp, Northern Trust Corp, Moderna, Inc., and AbbVie, Inc. Among individual investors, Michael Klichinsky owns the most shares of Carisma Therapeutics (CARM).